Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 4/2013

01.08.2013 | Microvascular Complications-Retinopathy (JK Sun, Section Editor)

Current State of Care for Diabetic Retinopathy in India

verfasst von: Kim Ramasamy, Rajiv Raman, Manish Tandon

Erschienen in: Current Diabetes Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

In this article we review the current state of care of diabetic retinopathy in India. We discuss the magnitude of the problem; diabetes, and diabetic retinopathy in India. We highlight the causes of vision loss in diabetic retinopathy. The current level of awareness among general population and physicians is a concern. Current screening strategies practiced in India and the situational analysis of ophthalmologists in India are also reviewed. We review the current management of diabetic macular edema and proliferative diabetic retinopathy. To know the current practice pattern among retinal surgeons in India, a survey was done and the results of the survey are presented. There are few studies in the Indian population which have found some genetic risk and protective factors and a summary of these studies are also presented in this article.
Literatur
1.
Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12:346–54.PubMedCrossRef
2.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025 prevalence, numerical estimates and projection. Diabetes Care. 1998;21:1414–31.PubMedCrossRef
3.
Ramachandran A, Jali MV, Mohan V, Snehalatha C, Viswanathan M. High prevalence of diabetes in an urban population in South India. BMJ. 1988;297:587–90.PubMedCrossRef
4.
Ramachandran A, Snehalatha C, Dharmaraj D, Viswanathan M. Prevalence of glucose intolerance in Asian Indians: urban–rural difference and significance of upper body adiposity. Diabetes Care. 1992;15:1348–55.PubMedCrossRef
5.
Rani PK, Raman R, Sharma V, et al. Analysis of a comprehensive diabetic retinopathy screening model for rural and urban diabetics in developing countries. Br J Ophthalmol. 2007;91:1425–9.PubMedCrossRef
6.
• Namperumalsamy P, Kim R, Vignesh TP, Nithya N, Royes J, Gijo T, et al. Prevalence and risk factors for diabetic retinopathy: a population-based assessment from Theni District, south India. Br J Ophthalmol. 2009;93:429–34. doi:10.​1136/​bjo.​2008.​147934. This study is the first population-based study in Rural India for elucidating the prevalence and risk factors for diabetic retinopathy.
7.
• Raman R, Rani PK, Reddi Rachepalle S, Gnanamoorthy P, Uthra S, Kumaramanickavel G, et al. Prevalence of diabetic retinopathy in India: Sankara Nethralaya diabetic retinopathy epidemiology and molecular genetics study report 2. Ophthalmology. 2009;116:311–8. This study is the first population-based study in Urban India for elucidating the prevalence and risk factors for diabetic retinopathy.
8.
Rema M, Pradeepa R. Diabetic retinopathy: an Indian perspective. Indian J Med Res. 2007;125:297–310. Review.PubMed
9.
Narendran V, John RK, Raghuram A,Ravindran RD, Nirmalan PK, Thulasiraj RD. Diabetic retinopathy among self reported diabetics in southern India: a population based assessment. Br J Ophthalmol. 2002;86:1014–8.
10.
Leske MC, Wu SY, Hyman L, Li X, Hennis A, Connell AM, et al. Diabetic retinopathy in a black population: the Barbados Eye Study. Ophthalmology. 1999;106:1893–9. Erratum in: Ophthalmology. 2000;107:412.
11.
Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology. 1998;105(3):406–11.
12.
Wilkinson CP, Ferris III FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.
13.
Liu WJ, Lee LT, Yen MF, Tung TH, Williams R,Duffy SW, et al. Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: implication for diabetic retinopathy screening in Taiwan. Diabet Med. 2003;20:727–33.
14.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
15.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
16.
The Diabetic Retinopathy Study Research Group. Clinical application of diabetic retinopathy study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88:583–600.
17.
Early Treatment Diabetic Retinopathy Study research group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766–85.
18.
Namperumalsamy P, Kim R, Kaliaperumal K, Sekar A, Karthika A, Nirmalan PK, et al. A pilot study on awareness of diabetic retinopathy among non-medical persons in South India. The challenge for eye care progams in the region. Indian J Ophthalmol. 2004;52:247–51.
19.
20.
Lecaire TJ, Palta M, Klein R, Klein BE, Cruickshanks KJ. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 2013;36(3):631–7.
21.
Namperumalsamy P, Nirmalan PK, Ramasamy K. Developing a screening program to detect sight-threatening diabetic retinopathy in south India. Diabetes Care. 2003;26:1831–5.
22.
Rani PK, Raman R, Agarwal S, Paul PG, Uthra S, Margabandhu G, et al. Diabetic retinopathy screening model for rural population: awareness and screening methodology. Rural Remote Heal. 2005;5:350.
23.
Liesenfeld B, Kohner E, Piehlmeier W, Kluthe S, Aldington S, Porta M, et al. A telemedical approach to the screening of diabetic retinopathy digital fundus photography. Diabetes Care. 2000;23:345–48.
24.
Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology. 2012. [Epub ahead of print].
25.
Raman R, Mahajan S, Padmaja RK, Agarwal S, Gnanamoorthy P, Paul PG. Tele-health program for diabetic retinopathy in rural South India: a pilot study. E-Health Int. 2005;2:13–18.
26.
Raman R, Paul PG, Padmajakumari R, Sharma T. Knowledge and attitude of general practitioners towards diabetic retinopathy practice in South India. Community Eye Health. 2006;19(57):13–4.
27.
Kumar R. Ophthalmic manpower in India — need for a serious review. Int Ophthalmol. 1993;17:269–75.PubMedCrossRef
28.
• Raman R, Gupta A, Kulothungan V, Sharma T. Prevalence and risk factors of diabetic retinopathy in subjects with suboptimal glycemic, blood pressure, and lipid control. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 33). Curr Eye Res. 2012;37(6):513–23. This study highlights the prevalence of suboptimal control of glycemic parameters in the Indian population.
29.
Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8(4):274–84. Review.
30.
Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127(3):245–51.
31.
Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14.CrossRef
32.
Vinores SA, Youssri AL, Luna JD, Chen YS, Bhargave S, Vinores MA, et al. Upregulation of vascular endothelial growth factor in ischemic and nonischemic human and experimental retinal disease. Histology Histopathol. 199;12(1):99–109.
33.
Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-month data: report 2. Ophthalmology. 2010;117(6):1078–86.
34.
Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (bolt study): report 1. Retina. 2010;30(5):781–86.
35.
Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–51.
36.
Elman MJ, Bressler NM, Qin H, Beck RW, Ferris III FL, Friedman SM, et al. Expanded 2- year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14.
37.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser vs laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–25.
38.
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema; results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
39.
Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, et al. The da VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819–26.
40.
Diabetic retinopathy vitrectomy study research group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four year results of a randomized trial. Diabetic retinopathy vitrectomy study report 5. Arch Ophthalmol. 1990;108:958–64.
41.
Lewis H, Abrams GW, Blumenkranz MS, Schrooyen M. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloid traction. Ophthalmology. 1992;99:753–59.
42.
Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20:126–33.
43.
Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research Network. Retina. 2010;30(9):1488–95.
44.
• Jumper JM, Mittra RA, editors. ASRS 2012 preferences and trends membership survey. Chicago: American Society of Retina Specialists. 2012. This survey was done by American Society of Retina specialists to know the preferences and trends in retina practice in US and members of society from other countries.
45.
Balasubbu S, Sundaresan P, Rajendran A, Ramasamy K, Govindarajan G, Perumalsamy N, et al. Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 Diabetic retinopathy. BMC Med Genet. 2010;11:158.
46.
Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T, et al. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet. 2003;24(1):41–8.
47.
Uthra S, Raman R, Mukesh BN, Rajkumar SA, Kumari RP, Agarwal S, et al. Diabetic retinopathy and IGF-1 gene polymorphic cytosine-adenine repeats in a Southern Indian cohort. Ophthalmic Res. 2007;39(5):294–9.
48.
Vinita K, Sripriya S, Prathiba K, Vaitheeswaran K, Sathyabaarathi R, Rajesh M, et al. ICAM-1 K469E polymorphism is a genetic determinant for the clinical risk factors of T2D subjects with retinopathy in Indians: a population-based case–control study. BMJ Open. 2012;2(4). pii: e001036.
49.
Kumaramanickavel G, Sripriya S, Vellanki RN, Upadyay NK, Badrinath SS, Arokiasamy T, et al. Tumor necrosis factor allelic polymorphism with diabetic retinopathy in India. Diabetes Res Clin Pract. 2001;54:89–94.
50.
Kumaramanickavel G, Sripriya S, Vellanki RN, Upadyay NK, Badrinath SS, Rajendran V, et al. Inducible nitric oxide synthase gene and diabetic retinopathy in Asian Indian patients. Clin Genet. 2002;61:344–8.
51.
Kumaramanickavel G, Ramprasad VL, Sripriya S, Upadyay NK, Paul PG, Sharma T, et al. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. J Diabetes Complications. 2002;16:391–94.
52.
Uthra S, Raman R, Mukesh BN, Rajkumar SA, Kumari PR, Lakshmipathy P, et al. Protein kinase C beta (PRKCB1) and pigment epithelium derived factor (PEDF) gene polymorphisms and diabetic retinopathy in a south Indian cohort. Ophthalmic Genet. 2010;31(1):18–23.
53.
Uthra S, Raman R, Mukesh BN, Rajkumar SA, Padmaja KR, Paul PG, et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet. 2008;29(1):11–5.
54.
Uthra S, Raman R, Mukesh BN, PadmajaKumari R, Paul PG, Lakshmipathy P, et al. Intron 4 VNTR of endothelial nitric oxide synthase (eNOS) gene and diabetic retinopathy in type 2 patients in southern India. Ophthalmic Genet. 2007;28(2):77–81.
Metadaten
Titel
Current State of Care for Diabetic Retinopathy in India
verfasst von
Kim Ramasamy
Rajiv Raman
Manish Tandon
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 4/2013
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-013-0388-6

Weitere Artikel der Ausgabe 4/2013

Current Diabetes Reports 4/2013 Zur Ausgabe

Microvascular Complications-Neuropathy (D Ziegler, Section Editor)

Corneal Confocal Microscopy: A New Technique for Early Detection of Diabetic Neuropathy

Microvascular Complications-Retinopathy (JK Sun, Section Editor)

Imaging of the Parafoveal Capillary Network in Diabetes

Microvascular Complications-Nephropathy (B Roshan, Section Editor)

Novel Biomarkers for the Progression of Diabetic Nephropathy: Soluble TNF Receptors

Microvascular Complications-Nephropathy (B Roshan, Section Editor)

Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Kidney Disease

Microvascular Complications-Neuropathy (D Ziegler, Section Editor)

Neurovascular Function and Sudorimetry in Health and Disease

Microvascular Complications-Neuropathy (D Ziegler, Section Editor)

Magnetic Resonance Imaging of the Central Nervous System in Diabetic Neuropathy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise